Nonpeptide urotensin-II receptor antagonists: A new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits

Journal of Medicinal Chemistry

Volumn 52, Issue 23, 2009, Pages 7432-7445

  Lawson, Edward C ^a   Luci, Diane K ^a   Ghosh, Shyamali ^a   Kinney, William A ^a   Reynolds, Charles H ^a   Qi, Jenson ^a   Smith, Charles E ^a   Wang, Yuanping ^a   Minor, Lisa K ^a   Haertlein, Barbara J ^a   Parry, Tom J ^a   Damiano, Bruce P ^a   Maryanoff, Bruce E ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (BENZYL) PIPERAZIN 1 YL] 2 (3,4 DIMETHOXYBENZYL) 2,3 DIHYDRO 1H ISOINDOLE 1,3 DIONE; G PROTEIN COUPLED RECEPTOR; LIGAND; N (2 THIOPHENECARBONYL) {4 (3,4 DIMETHOXYPHENYL) 4 [4 (4 ETHYLPIPERAZIN 1 YL) 1 OXO 2,3 DIHYDRO 1H ISOINDOL 2 YL]BUTYL} AMIDE; N (2 THIOPHENESULFONYL) [4 (3,4 DIMETHOXYPHENYL)] 4 {1,3 DIOXO 4 [4 (1 PHENYLETHYL)PIPERAZIN 1 YL] 2,3 DIHYDRO 1H ISOINDOL 2 YL}BUTYL AMIDE); N (2 THIOPHENESULFONYL) {4 (3,4 DIMETHOXYPHENYL) 4 [4 (4 ETHYLPIPERAZIN 1 YL) 1 OXO 2,3 DIHYDRO 1H ISOINDOL 2 YL] BUTYL}AMIDE; PHTHALIMIDE DERIVATIVE; PIPERAZINO ISOINDOLINONE; PIPERAZINO PHTHALIMIDE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UROTENSIN RECEPTOR;

ARTICLE; CALCIUM TRANSPORT; COLUMN CHROMATOGRAPHY; CONFORMATIONAL TRANSITION; DRUG ANTAGONISM; ENANTIOSELECTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IC 50; IN VITRO STUDY; NONHUMAN; PHARMACOPHORE; PROTEIN BINDING; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOASSAY; RAT; SYNTHESIS; VASCULAR RING;

ANIMALS; AORTA; CHO CELLS; CRICETINAE; CRICETULUS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ISOINDOLES; MALE; PHTHALIMIDES; PIPERAZINES; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 72249117763     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900683d     Document Type: Article

References (73)

1. For reviews, see: (a) Onan, D.; Hannan, R. D.; Thomas, W. G. Urotensin II: the old kid in town.TrendsEndocrinol.Metab. 2004, 15, 175-182.
2. (b) Doggrell, S. A. Urotensin-II and the cardiovascular system - the importance of developing modulators. Expert Opin. Investig. Drugs 2004, 13, 479-487.
3. (c) Douglas, S. A.; Dhanak, D.; Johns, D. G. From "gills to pills": urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol. Sci. 2004, 25, 76-85.
4. (d) Ong, K. L.; Lam, K. S. L.; Cheung, B. M. Y. Urotensin II: its function in health and its role in disease. Cardiovasc. Drugs Ther. 2005, 19, 65-75.
5. (e) Carmine, Z.; Mallamaci, F. Urotensin II: a cardiovascular and renal update. Curr. Opin. Nephrol. Hypertens. 2008, 17, 199-204.
6. (f) Proulx, C. D.; Holleran, B. J.; Lavigne, P.; Escher, E.; Guillemette, G.; Leduc, R. Biological properties and functional determinants of the urotensin II receptor. Peptides 2008, 29, 691-699.
7. (g) Maryanoff, B. E.; Kinney, W. A. Urotensin-II receptor modulators as potential drugs. J. Med. Chem., in press.
8. (a) Pearson,D.; Shively, J. E.; Clark, B.R.;Geschwind, I. I; Barkley, M.; Nishioka, R. S.; Bern, H. A. Urotensin II: A somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 5021-5024.
9. (b) Coulouarn, Y.; Lihrmann, I.; Jegou, S.; Anouar, Y.; Tostivint, H.; Beauvillain, J. C.; Conlon, J. M.; Bern, H. A.; Vaudry, H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene inmotoneurons of the spinal cord. Proc.Natl. Acad. Sci. U.S.A. 1998, 95, 15803-15808.
10. (c) Ames, R. S.; Sarau, H. M.; Chambers, J. K.; Willette, R. N.; Aiyar, N. V.; Romanic, A. M.; Louden, C. S.; Foley, J. J.; Sauermelch, C. F.; Coatney, R. W.; Ao, Z.; Disa, J.; Holmes, S. D.; Stadel, J. M.; Martin, J. D.; Liu, W.-S.; Glover, G. I.; Wilson, S.; McNulty, D. E.; Ellis, C. E.; Elshourbagy, N. A.; Shabon, U.; Trill, J. J.; Hay, D. W. P.; Ohlstein, E. H.; Bergsma, D. J.; Douglas, S. A. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999, 401, 282-286. (Pubitemid 129515542)
11. (d) Elshourbagy, N. A.; Douglas, S. A.; Shabon, U.; Harrison, S.; Duddy, G.; Sechler, J. L.; Ao, Z.; Maleeff, B. E.; Naselsky, D.; Disa, J.; Aiyar, N. V. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br. J. Pharmacol. 2002, 136, 9-22.
12. (e) Maguire, J. J.; Kuc, R. E.; Kleinz, M. J.; Davenport, A. P. Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function. Peptides 2008, 29, 735-742.
13. (a) Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Fournier, A.; Klabunde, T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J. Med. Chem. 2002, 45, 1799-1805.
14. (b) Kinney, W. A.; Almond, H. R., Jr.; Qi, J.; Smith, C. E.; Santulli, R. J.; de Garavilla, L.; Andrade-Gordon, P.; Cho, D. S.; Everson, A. M.; Feinstein, M. A.; Leung, P. A.; Maryanoff, B. E. Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew. Chem., Int. Ed. 2002, 41, 2940-2944.
15. (c) Brkovic, A.; Hattenberger, A.; Kostenis, E.; Klabunde, T.; Flohr, S.; Kurz, M.; Bourgault, S.; Fournier, A. Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay. J. Pharmacol. Exp. Ther. 2003, 306, 1200-1209.
16. Conlon, J. M.; Yano, K.; Waugh, D.; Hazon, N. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J. Exp. Zool. 1996, 275, 226-238.
17. Bohm, F.; Pernow, J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br. J. Pharmacol. 2002, 135, 25-27.
18. Douglas, S. A.; Ohlstein, E. H. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc. Med. 2000, 10, 229-237.
19. Gardiner, S. M.; March, J. E.; Kemp, P. A.; Davenport, A. P.; Bennett, T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br. J. Pharmacol. 2001, 132, 1625-1629.
20. Zou, Y.; Nagai, R.; Yamazaki, T. Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett. 2001, 508, 57-60. (Pubitemid 33055667)
21. Watanabe, T.; Pakala, R.; Katagiri, T.; Benedict, C. R. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 2001, 104, 16-18.
22. (a) Matsushita, M.; Shichiri, M.; Imai, T.; Iwashina, M.; Tanaka, H.; Takasu, N.; Hirata, Y. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J. Hypertens. 2001, 19, 2185-2190. (Pubitemid 33135240)
23. (b) Krum, H.; Kemp,W. Therapeutic potential of blockade of the urotensin II system in systemic hypertension. Curr. Hypertens. Rep. 2007, 9, 53-58.
24. (a) Douglas, S. A.; Tayara, L.; Ohlstein, E. H.; Halawa, N.; Giaid, A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002, 359, 1990-1997.
25. (b) Tzanidis, A.; Hannan, R. D.; Thomas,W. G.; Onan, D.; Autelitano,D. J.; See, F.; Kelly, D. J.; Gilbert, R. E.; Krum, H. Direct actions of urotensin II on the heart. Implications for cardiac fibrosis and hypertrophy. Circ. Res. 2003, 93, 246-253.
26. (c) Tolle, M.; van der Giet, M. Cardiorenovascular effects of urotensin II and the relevance of the UT receptor. Peptides 2008, 29, 743-763.
27. (a) Totsune, K.; Takahashi, K.; Arihara, Z.; Sone, M.; Satoh, F.; Ito, S.; Kimura, Y.; Sasano, H.; Murakami, O. Role of urotensin II in patients on dialysis. Lancet 2001, 358, 810-811.
28. (b) Langham, R. G.; Kelly, D. J.; Gow, R. M.; Zhang, Y.; Dowling, J. K.; Thomson, N. M.; Gilbert, R. E. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am. J. Kidney Dis. 2004, 44, 826-831.
29. (a) Totsune, K.; Takahashi, K.; Arihara, Z.; Sone, M.; Ito, S.; Murakami, O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin. Sci. 2003, 104, 1-5.
30. (b) Wenyi, Z.; Suzuki, S.; Hirai, M.; Hinokio, Y.; Tanizawa, Y.; Matsutani, A.; Satoh, J.; Oka, Y. Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. Diabetologia 2003, 46, 972-976. (Pubitemid 36961321)
31. (c) Ong, K. L.;Wong, L. Y. F.; Cheung, B. M. Y. The role of urotensin II in the metabolic syndrome. Peptides 2008, 29, 859-867.
32. (a) Watanabe, T.; Kanome, T.; Suguro, T.; Miyazaki, A. Human urotensin II and metabolic syndrome. Vasc. Dis. Prev. 2006, 3, 91-98.
33. (b) Bousette, N.; Patel, L.; Douglas, S. A.; Ohlstein, E. H.; Giaid, A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004, 176, 117-123. (Pubitemid 39078653)
34. (c) Loirand, G.; Rolli-Derkinderen, M.; Pacaud, P. Urotensin II and atherosclerosis. Peptides 2008, 29, 778-782.
35. Luci, D. K.; Ghosh, S.; Smith, C. E.; Qi, J.; Wang, Y.; Haertlein, B.; Parry, T. J.; Li, J.; Almond, H. R.; Minor, L. K.; Damiano, B. P.; Kinney, W. A.; Maryanoff, B. E.; Lawson, E. C. Phenylpiperidinebenzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment. Bioorg. Med. Chem. Lett. 2007, 17, 6489-6492.
36. For reviews, see: (a) Jin, J.; Douglas, S. A. Non-peptidic urotensin- II receptor modulators. Expert Opin. Ther. Pat. 2006, 16, 467-479.
37. (b) Carotenuto, A.; Grieco, P.; Rovero, P.; Novellino, E. Urotensin-II receptor antagonists. Curr. Med. Chem. 2006, 13, 267-275.
38. (c) Lescot, E.; Bureau, R.; Rault, S. Nonpeptide urotensin-II receptor agonists and antagonists: review and structure-activity relationships. Peptides 2008, 29, 680-690.
39. (a) Jin, J.; Wang, Y.; Wang, F.; Shi, D.; Erhard, K. F.; Wu, Z.; Guida, B. F.; Lawrence, S. K.; Behm, D. J.; Disa, J.; Vaidya, K. S.; Evans,C.; McMillan, L. J.; Rivero,R.A.; Neeb,M. J.; Douglas, S. A. 2-Aminomethyl piperidines as novel urotensin-II receptor antagonists. Bioorg.Med. Chem. Lett. 2008, 18, 2860-2864.
40. (b) Jin, J.; Dhanak, D.; Knight, S. D.; Widdowson, K.; Aiyar, N.; Naselsky, D.; Sarau, H. M.; Foley, J. J.; Schmidt, D. B.; Bennett, C. D.; Wang, B.; Warren, G. L.; Moore, M. L.; Keenan, R. M.; Rivero, R. A.; Douglas, S. A. Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists. Bioorg.Med. Chem. Lett. 2005, 15, 3229-3232.
41. (c) Clozel, M.; Hess, P.; Qiu, C.; Ding, S. S.; Rey, M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J. Pharmacol. Exp. Ther. 2006, 316, 1115-1121.
42. (d) McAtee, J. J.; Dodson, J. W.; Dowdell, S. E.; Girard, G. R.; Goodman, K. B.; Hilfiker, M. A.; Sehon, C. A.; Sha, D.; Wang, G. Z.; Wang, N.; Viet, A. Q.; Zhang, D.; Aiyar, N. V.; Behm, D. J.; Carballo, L.H.; Evans, C. A.; Fries, H. E.; Nagilla, R.; Roethke, T. J.; Xu, X.; Yuan, C. C. K.; Douglas, S. A.; Neeb, M. J. Development of potent and selective small-molecule human urotensin-II antagonists. Bioorg. Med. Chem. Lett. 2008, 18, 3500-3503.
43. (e) McAtee, J. J.; Dodson, J. W.; Dowdell, S. E.; Erhard, K.; Girard, G. R.; Goodman, K. B.; Hilfiker, M. A.; Jin, J.; Sehon, C. A.; Sha, D.; Shi, D.; Wang, F.; Wang, G. Z.; Wang, N.; Wang, Y.; Viet, A. Q.; Yuan, C. C. K.; Zhang, D.; Aiyar, N. V.; Behm, D. J.; Carballo, L. H.; Evans, C. A.; Fries, H. E.; Nagilla, R.; Roethke, T. J.; Xu, X.; Douglas, S. A.; Neeb, M. J. Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles. Bioorg. Med. Chem. Lett. 2008, 18, 3716-3719.
44. (f) Jin, J.; An, M.; Sapienza, A.; Aiyar, N.; Naselsky, D.; Sarau, H. M.; Foley, J. J.; Salyers, K. L.; Knight, S. D.; Keenan, R. M.; Rivero, R. A.; Dhanak, D.; Douglas, S. A. Urotensin-II receptor antagonists: Synthesis and SAR of N-cyclic azaalkyl benzamides. Bioorg. Med. Chem. Lett. 2008, 18, 3950-3954.
45. (g) Hilfiker, M. A.; Zhang, D.; Dowdell, S. E.; Goodman, K. B.; McAtee, J. J.; Dodson, J. W.; Viet, A. Q.; Wang, G. Z.; Sehon, C. A.; Behm, D. J.; Wu, Z.; Carballo, L. H.; Douglas, S. A.; Neeb, M. J. Aminomethylpiperazines as selective urotensin antagonists. Bioorg. Med. Chem. Lett. 2008, 18, 4470-4473.
46. (h) Wang, Y.; Wu, Z.; Guida, B. F.; Lawrence, S. K.; Neeb, M. J.; Rivero, R. A.; Douglas, S. A.; Jin, J. N-Alkyl-5H-pyrido[4,3-b]indol-1-amines and derivatives as novel urotensin-II receptor antagonists. Bioorg. Med. Chem. Lett. 2008, 18, 4936-4939.
47. (i) Clozel, M.; Binkert, C.; Birker-Robaczewska, M.; Boukhadra, C.; Ding, S.-S.; Fischli, W.; Hess, P.; Mathys, B.; Morrison, K.; Mueller, C.; Mueller, C.; Nayler, O.; Qiu, C.; Rey, M.; Scherz, M. W.; Velker, J.; Weller, T.; Xi, J.-F.; Ziltener, P. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)-ethyl]-3-(2- methylquinolin-4-yl)urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J. Pharmacol. Exp. Ther. 2004, 311, 204-212.
48. Nahm, S.; Weinreb, S. M. N-Methoxy-N-methylamides as effective acylating agents. Tetrahedron Lett. 1981, 22, 3815-3818.
49. Ponzo, V. L.; Kaufman, T. S. A simple protocol for the one pot synthesis of chiral secondary benzylic alcohols by catalytic enantioselective reduction of aromatic ketones. Synlett 2002, 7, 1128-1130.
50. Garro-Helion, F.; Merzouk, A.; Guibe, F. Mild and selective palladium(0)-catalyzed deallylation of allylic amines. Allylamine and diallylamine as very convenient ammonia equivalents for the synthesis of primary amines. J. Org. Chem. 1993, 58, 6109-6113.
51. (a) Kadyrov, R; Riermeier, T. H. Highly enantioselective hydrogen- transfer reductive amination: catalytic asymmetric synthesis of primary amines. Angew. Chem., Int. Ed. 2003, 42, 5472-5474.
52. (b) Each enantiomer of intermediate XV was analyzed by chiral HPLC (seeExperimental Section).
53. Kuwano, R.; Utsunomiya, M.; Hartwig, J. F. Aqueous hydroxide as a base for palladium-catalyzed amination of aryl chlorides and bromides. J. Org. Chem. 2002, 67, 6479-6486.
54. 50 value of 460 nM.
55. Qi, J.-S.; Minor, L. K.; Smith, C.; Hu, B.; Yang, J.; Andrade- Gordon, P.; Damiano, B. Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors. Peptides 2005, 26, 683-690. (Pubitemid 40326887)
56. 50=150 nM).
57. Douglas, S. A.; Behm, D. J.; Aiyar, N. V.; Naselsky, D.; Disa, J.; Brooks, D. P.; Ohlstein, E. H.; Gleason, J. G.; Sarau, H. M.; Foley, J. J.; Buckley, P. T.; Schmidt, D. B.; Wixted,W. E.; Widdowson, K.; Riley, G.; Jin, J.; Gallagher, T. F.; Schmidt, S. J.; Ridgers, L.; Christmann, L. T.; Keenan, R. M.; Knight, S. D.; Dhanak, D. Nonpeptidic urotensin- II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br. J. Pharmacol. 2005, 145, 620-635.
58. Herold, C. L.; Behm, D. J.; Buckley, P. T.; Foley, J. J.; Wixted, W. E.; Sarau, H. M.; Douglas, S. A. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. Br. J. Pharmacol. 2003, 139, 203-207.
59. Qi, J.; Schulingkamp, R.; Parry, T. J.; Colburn, R.; Stone, D.; Haertlein, B.; Minor, L. K.; Andrade-Gordon, P.; Damiano, B. P. Urotensin-II induces ear flushing in rats. Br. J. Pharmacol. 2007, 150, 415-423.
60. Cerep (Seattle, WA; www.cerep.com), an independent contract laboratory, performed standardized binding assays on receptors and ion channels. Each results was expressed as percent inhibition of a control specific binding (mean values, n=2; h, human).
61. + channel; Cl- channel; norepinephrine transporter; dopamine transporter.
62. Maestro 8.5.207; Schrodinger, Inc.: 1500 SW First Avenue, Suite 1180, Portland, OR.
63. Jorgensen,W. L.; Tirado-Rives, J. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J. Am. Chem. Soc. 1988, 110, 1657-1666.
64. Qui, D.; Shenkin, P. S.; Hollinger, F. P.; Still, C. W. The GB/SA continuum model for solvation. A fast analytical method for the calculation of approximate Born radii. J. Phys. Chem. A 1997, 101, 3005-3014.
65. (a) Kolossvary, I.; Guida, W. C. Low mode search. An efficient, automated computational method for conformational analysis: application to cyclic and acyclic alkanes and cyclic peptides. J. Am. Chem. Soc. 1996, 118, 5011-5019.
66. 80 and flexible docking of 9-deazaguanine inhibitors into PNP. J. Comput. Chem. 1999, 20, 1671-1684.
67. Phase, Version 3.0; Schrodinger, LLC: New York, 2008.
68. Luci, D. K.; Lawson, E. C.; Ghosh, S.; Kinney, W. A.; Smith, C. E.; Qi, J.; Wang, Y.; Minor, L. K.; Maryanoff, B. E. Generation of novel, potent urotensin-II receptor antagonists by alkylation-cyclization of isoindolinone C3-carbanions. Tetrahedron Lett. 2009, 50, 4958-4961.
69. (a) Lescot, E.; Sopkova-de Oliveira Santos, J.; Dubessy, C.; Oulyadi, H.; Lesnard, A.; Vaudry, H.; Bureau, R.; Rault, S. Definition of new pharmacophores for nonpeptide antagonists of urotensin-II. Comparison with the 3D-structure of human urotensin- II and URP. J. Chem. Inf. Model. 2007, 47, 602-612.
70. (b) Lescot, E.; Sopkova-de Oliveira Santos, J.; Colloc'h, N.; Rodrigo, J.; Milazzo- Segalas, I.; Bureau, R.; Rault, S. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model. Proteins 2008, 73, 173-184.
71. Kitamura, M.; Tokunaga, M.; Ohkuma, T.; Noyori, R. Asymmetric hydrogenation of 3-oxo carboxylates using BINAP-ruthenium complexes: (R)-(-)-methyl 3-hydroxybutanoate. Org. Synth. 1993, 71, 1-13.
72. (a) Tal, M.; Ammar, D. A.; Karpuj, M.; Krizhanovsky, V.; Naim, M.; Thompson, D. A. A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. Biochem. Biophys. Res. Commun. 1995, 209, 752-759.
73. (b) Marchese, A.; Heiber, M.; Nguyen, T.; Heng, H. H.; Saldivia, V. R.; Cheng, R.; Murphy, P. M.; Tsui, L. C.; Shi, X.; Gregor, P. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 1995, 29, 335-344.